These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25084549)

  • 1. Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum.
    Ríos JA; Cisternas P; Arrese M; Barja S; Inestrosa NC
    Prog Neurobiol; 2014 Oct; 121():125-46. PubMed ID: 25084549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How does brain insulin resistance develop in Alzheimer's disease?
    De Felice FG; Lourenco MV; Ferreira ST
    Alzheimers Dement; 2014 Feb; 10(1 Suppl):S26-32. PubMed ID: 24529521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease.
    Fuentealba RA; Farias G; Scheu J; Bronfman M; Marzolo MP; Inestrosa NC
    Brain Res Brain Res Rev; 2004 Dec; 47(1-3):275-89. PubMed ID: 15572177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease.
    Furiya Y; Ryo M; Kawahara M; Kiriyama T; Morikawa M; Ueno S
    Alzheimers Dement; 2013 Sep; 9(5):512-8. PubMed ID: 23142434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the Role of WNT Signaling in Metabolic Syndrome-Linked Alzheimer's Disease.
    Ali A; Ali A; Ahmad W; Ahmad N; Khan S; Nuruddin SM; Husain I
    Mol Neurobiol; 2020 Jan; 57(1):302-314. PubMed ID: 31325024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Wnt signaling in the development of Alzheimer's disease: a potential therapeutic target?
    Wan W; Xia S; Kalionis B; Liu L; Li Y
    Biomed Res Int; 2014; 2014():301575. PubMed ID: 24883305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease.
    Ferreira ST; Clarke JR; Bomfim TR; De Felice FG
    Alzheimers Dement; 2014 Feb; 10(1 Suppl):S76-83. PubMed ID: 24529528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockers and Alzheimer's disease: potential relevance in treatment strategies of metabolic syndrome.
    Goodison WV; Frisardi V; Kehoe PG
    J Alzheimers Dis; 2012; 30 Suppl 2():S269-82. PubMed ID: 22377784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alzheimer's disease and fragile X syndrome: the Wnt/ß-catenin pathway as a common biological mechanism].
    Rosales-Reynoso MA; Ochoa-Hernández AB; Juárez-Vázquez CI; Barros-Núñez P
    Rev Neurol; 2012 Nov; 55(9):543-8. PubMed ID: 23111993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular and metabolic dysfunction in Alzheimer's disease: a review.
    Murray IV; Proza JF; Sohrabji F; Lawler JM
    Exp Biol Med (Maywood); 2011 Jul; 236(7):772-82. PubMed ID: 21680755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease.
    Frisardi V; Solfrizzi V; Seripa D; Capurso C; Santamato A; Sancarlo D; Vendemiale G; Pilotto A; Panza F
    Ageing Res Rev; 2010 Oct; 9(4):399-417. PubMed ID: 20444434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt signaling in Alzheimer's disease: up or down, that is the question.
    Boonen RA; van Tijn P; Zivkovic D
    Ageing Res Rev; 2009 Apr; 8(2):71-82. PubMed ID: 19101658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consequences of Metabolic Disruption in Alzheimer's Disease Pathology.
    Ryu JC; Zimmer ER; Rosa-Neto P; Yoon SO
    Neurotherapeutics; 2019 Jul; 16(3):600-610. PubMed ID: 31270743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism.
    Nixon DW
    Curr Alzheimer Res; 2017; 14(8):883-893. PubMed ID: 28215174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin Dysfunction and Alzheimer's Disease: Evidence from Cellular, Animal, and Human Studies.
    McGuire MJ; Ishii M
    Cell Mol Neurobiol; 2016 Mar; 36(2):203-17. PubMed ID: 26993509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octodon degus: a model for the cognitive impairment associated with Alzheimer's disease.
    Tarragon E; Lopez D; Estrada C; Ana GC; Schenker E; Pifferi F; Bordet R; Richardson JC; Herrero MT
    CNS Neurosci Ther; 2013 Sep; 19(9):643-8. PubMed ID: 23710760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-lived Octodon degus as a rodent drug discovery model for Alzheimer's and other age-related diseases.
    Hurley MJ; Deacon RMJ; Beyer K; Ioannou E; Ibáñez A; Teeling JL; Cogram P
    Pharmacol Ther; 2018 Aug; 188():36-44. PubMed ID: 29514054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt signaling in the nervous system and in Alzheimer's disease.
    Inestrosa NC; Varela-Nallar L
    J Mol Cell Biol; 2014 Feb; 6(1):64-74. PubMed ID: 24549157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.